Andersons pediatric cardiology 2371
Bạn đang xem bản rút gọn của tài liệu. Xem và tải ngay bản đầy đủ của tài liệu tại đây (75.85 KB, 3 trang )
thromboembolismin,767
Petersonelasticmodulus,arterialstiffnessand,1362t
PFTE,Polytetrafluoroethylene
pH,incardiacsurgery,1399
Pharmacodynamics,1430
Pharmacogenetics,1430
Pharmacogenomics,1430
Pharmacokinetics,1430
Pharyngealarcharteries,developmentof,901–902,903f–905f
Phasecontrastflowmapping,320t–321t
Phenotype-genotypecorrelationstudies,1407
Phenotypescreening,amongfirst-degreerelatives,1539,1540f
Phenoxymethylpenicillin,forrheumaticfeverprevention,1016t
Phenylephrine,foracutecirculatoryfailure,1184t
Pheochromocytoma,hypertensionand,1137–1138
Phosphodiesteraseinhibitors,forpulmonaryhypertension,1390
Phosphodiesterase-3inhibitors,foracutecirculatoryfailure,1183
PhosphorylaseBkinasedeficiency,cardiacinvolvementin,1089
Phrenicnerve,anatomyof,17,19f
Physiologicallybasedpharmacokineticsmodeling,1438,1438f
Piezoelectricalmaterials,forechocardiography,309
Piperacillin,forbloodculture-negativeendocarditis,1054t
Pituitarygigantism,cardiacinvolvementin,1096
PJRT,Permanentformofjunctionalreciprocatingtachycardia
Placenta,157
incomplexcongenitalcardiacdisease,1394–1396
incongenitalheartdisease,157–161,160f
summaryof,160–161,161f
developmentof,normal,157–158,158f
dysfunctionof,mechanismsandconditionsof,158–159
fetalcirculationand,85–86,86f
insufficiencyof,159
smaller,159
Placentaltransfusion,inextremelyprematureneonate,190–191
Plan-do-study-actcycles,1506,1506f
Plasmaconcentrationvs.timecurve,1430f
Plasmaexchange,forKawasakisyndrome,990
Plasticbronchitis,inFontan-associatedliverdisease,1332–1333,1333f–1334f,
1333t
Plethysmogramwaveform,1366
Pleuraleffusions,superiorcavopulmonaryconnection,1299
Pneumonia,inrheumaticfever,1011
Polyaldehydecross-linkedbovineserumalbumin,inhemostasis,1289
Polyarteritisnodosa,cardiacinvolvementin,1110
Polyarthritis,inrheumaticfever,1009
Polyethyleneglycolhydrogels,inhemostasis,1289
Polymorphicventriculartachycardia,351,352f
“Polysplenia,”,441
Polytetrafluoroethylene(PFTE),220
Pompedisease,cardiacinvolvementin,1087–1088,1088f
cardiomyopathyashypertrophiccardiomyopathyand,1149
Poormetabolizerphenotype,1432
Portosystemicshunt,471
Positive-pressureventilation
inmodifiedFontanprocedure,1303
inmultidistributionandshock,1277
Positron-emissiontomography,exercisetestingand,397–398
Postconditioning,incardiopulmonarybypass,233
Posteroanteriorcamera,243
Postmortemcardiacmagneticresonance,330,330f
Postnatalgeneediting,82
Postnataltransition,prematurityand,189–190
Postoperativeechocardiography,300–301,301f
Postoperativeextracorporealsupport,incardiopulmonarybypass,233–234,234f
PostoperativeRastellipatients,indiagnosticcatheterization,247,247f
Postpericardiotomysyndrome,1070
Posttraumaticstressdisorder,initialICUstayon,1405–1406,1405f
Pottsshunt,forpulmonaryhypertension,1391
Power,statistical,413
PowerDoppler,inperfusionestimation,100,100f
Practiceguidelines,roleof,for“well”Fontan,1336–1337,1337f
Practicevariation,foruniventricularheart,1349–1350
Prazosinforhypertension,1140t
Precision,ofdata,410
Preconceptioncounselingwithcongenitalheartdisease,1442
Preconditioning,incardiopulmonarybypass,232
Prednisone,forcarditis,1017t
Pregnancy
anticoagulationand,1033–1034
cardiacmedicationsduring,1448
incongenitalheartdisease,1441–1449
contraceptionand,1442
globalassessmentofmaternalandfetalorneonatalrisksand,1443–1444,1443f,1444t,1444b,1445f
lesion-specificrisks,outcomes,andmanagementand,1444–1448
ofaorticcoarctation,1445
